

Short Form of the Stock: Sinopharm Accord /Accord B

China National Accord Medicines Corporation Ltd.

The First Quarterly Report for 2022

The Company and whole members of the BOD guarantee that the information disclosed is true, accurate and complete, and there are no any fictitious records, misleading statements or important omissions.

Important content reminder:

1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.

2. Principal of the Company, Person in Charge of Accounting Works and Person in Charge of Accounting Organ (Accounting Officer) hereby confirm that the Financial Report of the First Quarterly Report is authentic, accurate and complete.

3. Whether the First Quarterly Report has been audited or not

Yes No

I. Main financial data

(i) Main accounting data and financial indexes

Whether it has retroactive adjustment or re-statement on previous accounting data or not

Yes No

	Current Period	Same period of last year	Changes of this period over same period of last year
Operating income (RMB)	17,150,856,946.54	16,049,966,325.75	6.86%
Net profit attributable to shareholders of the listed company (RMB)	252,361,872.69	328,800,560.24	-23.25%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses (RMB)	242,244,636.06	321,593,612.98	-24.67%
Net cash flow arising from operating activities (RMB)	-217,452,223.38	-306,748,999.24	29.11%
Basic earnings per share (RMB/Share)	0.59	0.77	-23.38%
Diluted earnings per share (RMB/Share)	0.59	0.77	-23.38%
Weighted average ROE	1.68%	2.33%	0.65 percentage points

			down
	End of this period	End of last period	Changes of this period-end over same period-end of last year
Total assets (RMB)	44,844,103,338.63	42,783,682,431.81	4.82%
Owners' equity attributable to shareholders of listed company (RMB)	15,177,183,542.81	14,924,938,052.50	1.69%

Explanation on the business performance and financial status:

The Company achieved operation income of 17,151 million yuan for the first quarter of 2022, a year-on-year increase of 6.86%; operation profit was 375 million yuan, 20.42% down from a year earlier; the net profit attributable to shareholder of listed company was 252 million yuan, decrease of 23.25% on a year-on-year basis, the basic EPS decreased by 23.38% correspondingly and weighted ROE decreased by 0.65 percentage points. Profit decline mainly due to the impact of COVID-19, the performance from affiliates declined and the investment earnings decreased accordingly. Meanwhile, the customer flow from retail segment drops due to the epidemic, and the new stores operated in 2021 have a large initial investment, the benefits are not yet visible with shrinking profit space.

The distribution segment has an operation income of 12,171 million yuan, a year-on-year growth of 7.45%; net profit was 210 million yuan, a year-on-year increase of 10.40%. the retail segment has 5,238 million yuan from the operation income, a year-on-year increase of 5.11% and achieved a net profit of 32 million yuan, down 63.80% on a year-on-year basis.

(ii) Items of non-recurring gains and losses

Applicable Not applicable

Unit: RMB/CNY

Item	Current amount	Note
Gains/losses from the disposal of non-current asset (including the write-off that accrued for impairment of assets)	785,738.83	The gains on disposal of right-to-use assets arising from off-lease in the period
Governmental subsidy calculated into current gains and losses(while closely related with the normal business of the Company, the government subsidy that accord with the provision of national policies and are continuously enjoyed in line with a certain standard quota or quantity are excluded)	15,562,891.34	Mainly the various special subsidies and tax rebates received in the Period
Reversal of the account receivable depreciation reserves subject to separate impairment test	1,632,768.34	
Other non-operating income and expenses other than the above	1,205,854.08	
Other gains/losses items that meet the definition of non-recurring gains/losses	1,789,818.44	
Less: impact on income tax	5,104,445.81	
Impact on minority shareholders' equity (post-tax)	5,755,388.59	
Total	10,117,236.63	--

Details of other gains/losses items that meet the definition of non-recurring gains/losses:

Applicable Not applicable

There are no other gains/losses items that meet the definition of non-recurring gains/losses in the Company.

Explain the items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in *Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss*

Applicable Not applicable

There are no items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in *Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss*

(iii) Particulars about material changes in items of main accounting statement and financial index and explanations of reasons

Applicable Not applicable

(1) Receivable financing: decrease of 557.8708 million yuan from beginning of the Period with a growth rate of -54.31%, mainly due to the increase in discounting of bank acceptance in the Period;

(2) Construction in progress: decrease of 15.0976 million yuan from beginning of the Period with a growth rate of -30.29%, mainly because the ERP project transfer-out after completion & acceptance;

(3) Short-term borrowings: increase of 1,108.1141 million yuan from beginning of the Period with a growth rate of 57.40%, mainly due to the increase in financing with the invoice of account payable;

(4) Employee benefits payable: decrease of 114.3872 million yuan from beginning of the Period with a growth rate of -33.62%, mainly because the wages and bonuses accrued in the prior year are paid in the Period;

(5) Other incomes: a year-on-year increase of 11.3852 million yuan with a growth rate of 83.37%, mainly because various subsidies received in the Period and the tax relief increased on a year-on-year basis;

(6) Investment income: a year-on-year decrease of 67.8440 million yuan with a growth rate of -74.30%, mainly because the performance from affiliates declined and the investment earnings decreased accordingly;

(7) Credit impairment losses: a year-on-year increase of 8.7011 million yuan with a growth rate of 50.60%, mainly due to the increase of account receivable at period-end compared to the same period of last year for the sales up; affected by the epidemic, medical insurance allocation was delayed, the capital operation from hospital are relatively tight which had a certain impact on the receivable collection of the Company, turnover days of the receivable increase to some extent, than the bad debt provision goes up correspondingly;

(8) Impairment losses: a year-on-year decrease of 1.8342 million yuan with a growth rate of -52.58%, mainly due to the decrease in provision for inventory falling price reserves on a year-on-year basis;

(9) Gain on disposal of assets: a year-on-year increase of 0.7065 million yuan with a growth rate of 259.86%, mainly due to the increase in earnings on a year-on-year basis, resulting from disposal of the right-of-use assets for vacating from retail stores.

(10) Non-operating income: a year-on-year decrease of 4.0821 million yuan with a growth rate of -64.08%, mainly because in the Period, the payable without payment requirements written off declined from a year earlier;

(11) Non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20%, mainly because the net profit attributable to owners of parent company from subsidiary-Sinopharm Holding Guoda Drugstore Co., Ltd.(hereinafter referred to as Guoda Drugstore) declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the strategic investor of the Group-Walgreens Boots Alliance(Hong Kong)Investments Limited (hereinafter referred to as WBA) decreased on a year-on-year basis;

(12) Total comprehensive income attributable to non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20%, mainly because the net profit attributable to owners of parent company from subsidiary-Guoda Drugstore declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the strategic investor of the Group- WBA decreased on a year-on-year basis;

(13) Receipts of taxes and surcharges refunds: a year-on-year decrease of 4.7192 million yuan with a growth rate of -84.00%, mainly

due to the year-on-year decline in enterprise income tax refunds received in the Period;

(14) Other cash receipts relating to operating activities: a year-on-year decrease of 64.1937 million yuan with a growth rate of -30.61%, mainly because the reserve funds for epidemic-specific, deposits and security deposit received in the Period declined from a year earlier;

(15) Cash receipts from returns of investments: a year-on-year decrease of 2.9974 million yuan with a growth rate of -100.00%, mainly because in same period of last year, received the withdrawal payment from part of the projects of Sinopharm Zhongjin Medical Industry Fund, and there was no such matter occurred in the Period;

(16) Cash received from investment income: a year-on-year decrease of 3.5996 million yuan with a growth rate of -100.00%, mainly because in same period of last year, received dividend payment from projects of Sinopharm Zhongjin Medical Industry Fund, and there was no such matter occurred in the Period;

(17) Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets: a year-on-year decrease of 0.2423 million yuan with a growth rate of -74.08%, mainly because the cash received in the Period from fixed assets disposal decreased from a year earlier;

(18) Total cash inflows from investing activities: a year-on-year decrease of 6.8393 million yuan with a growth rate of -98.78%, mainly because in same period of last year, received dividend payment and withdrawal payment from projects of Sinopharm Zhongjin Medical Industry Fund, and there were no such matters occurred in the Period;

(19) Cash payments for investments: a year-on-year decrease of 8.7574 million yuan with a growth rate of -32.34%, mainly because the payment for rental transfer fees in the Period declined from a year earlier, paid by subsidiary - Guoda Drugstore;

(20) Net cash payments for acquisition of subsidiaries and other business units: a year-on-year decrease of 73.1595 million yuan with a growth rate of -100.00%, mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was no such matter occurred in the Period;

(21) Total cash outflows from investing activities: a year-on-year decrease of 67.8542 million yuan with a growth rate of -41.83%, mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was no such matter occurred in the Period;

(22) Net cash flows from investing activities: a year-on-year increase of 61.0148 million yuan with a growth rate of 39.29%, mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was no such matter occurred in the Period;

(23) Cash proceeds from investments by others: a year-on-year decrease of 4.98 million yuan with a growth rate of -84.69%, mainly due to the year-on-year decrease in investment received from minority during the Period;

(24) Other cash receipts relating to financing activities: a year-on-year decrease of 192.0255 million yuan with a growth rate of -64.56%, mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis;

(25) Cash repayments for debts: a year-on-year increase of 94.2452 million yuan with a growth rate of 53.17%, mainly due to the increase in repayment of loans due in the Period;

(26) Total cash outflows from financing activities: a year-on-year increase of 161.1150 million yuan with a growth rate of 33.41%, mainly because repayment of loans from financial institutions and the rents paid for increasing retail stores in the Period increased on a year-on-year basis;

(27) Net cash flows from financing activities: a year-on-year decrease of 276.5162 million yuan with a growth rate of -71.17%, mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rents paid for increasing retail stores in the Period increased on a year-on-year basis;

(28) Effect of foreign exchange rate changes on cash and cash equivalents: a year-on-year increase of 1,989.89 yuan with a growth rate of 81.53%, mainly due to the change of exchange rates;

(29) Net increase of cash and cash equivalents :a year-on-year decrease of 126.2026 million yuan with a growth rate of -171.70%, mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rents paid for increasing retail stores in the Period increased on a year-on-year basis.

II. Shareholders

(i) Total number of common shareholders and preference shareholders with voting rights recovered and top ten shareholders

Unit: Share

Total number of common shareholders at the end of report period		44,112		Total preference shareholders with voting rights recovered at end of reporting period (if applicable)		0	
Top ten shareholders							
Shareholder's name	Nature of shareholder	Proportion of shares held	Amount of shares held	Amount of lock-up shares held	Information of shares pledged, tagged or frozen		
					State of share	Amount	
Sinopharm Group Co., Ltd.	State-owned Corporation	56.06%	239,999,991	5,505,770			
FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND	Foreign Corporation	2.52%	10,802,495				
Hong Kong Securities Clearing Company Ltd.	Foreign Corporation	2.28%	9,751,340				
China National Pharmaceutical Foreign Trade Corp.	State-owned Corporation	1.24%	5,323,043				
National Social Security Fund 413 Portfolio	Domestic non state-owned Corporation	1.07%	4,590,032				
BBH BOS S/A FIDELITY FD - CHINA FOCUS FD	Foreign Corporation	0.78%	3,358,761				
Fidelity Investment Management	Foreign Corporation	0.54%	2,301,737				

(Hong Kong) Limited - Client's fund						
ICBC-Guolian Andesheng Small Selected Securities Investment Fund	Domestic non state-owned Corporation	0.38%	1,632,000			
CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan	Domestic non state-owned Corporation	0.34%	1,470,224			
VANGUARD EMERGING MARKETS STOCK INDEX FUND	Foreign Corporation	0.34%	1,456,150			

Top ten shareholders with unrestricted shares held

Shareholder's name	Amount of unrestricted shares held	Type of shares	
		Type	Amount
Sinopharm Group Co., Ltd.	234,494,221	RMB ordinary shares	234,494,221
FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND	10,802,495	Domestically listed foreign shares	10,802,495
Hong Kong Securities Clearing Company Ltd.	9,751,340	RMB ordinary shares	9,751,340
China National Pharmaceutical Foreign Trade Corp.	5,323,043	RMB ordinary shares	5,323,043
National Social Security Fund 413 Portfolio	4,590,032	RMB ordinary shares	4,590,032

BBH BOS S/A FIDELITY FD - CHINA FOCUS FD	3,358,761	Domestically listed foreign shares	3,358,761
Fidelity Investment Management (Hong Kong) Limited - Client's fund	2,301,737	RMB ordinary shares	2,301,737
ICBC-Guolian Andesheng Small Selected Securities Investment Fund	1,632,000	RMB ordinary shares	1,632,000
CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan	1,470,224	RMB ordinary shares	1,470,224
VANGUARD EMERGING MARKETS STOCK INDEX FUND	1,456,150	Domestically listed foreign shares	1,456,150
Explanation on associated relationship among the aforesaid shareholders	Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies.		

(ii) Total shareholders with preferred stock held and shares held by top ten shareholders with preferred stock held

Applicable Not applicable

III. Other important matters

Applicable Not applicable

IV. Quarterly financial statements

(i) Financial statement

1. Consolidate Balance Sheet

Prepared by China National Accord Medicines Corporation Ltd.

March 31, 2022

Unit: RMB/CNY

Item	Ending balance	Opening balance
Current assets:		
Cash and bank balances	4,867,544,893.18	5,126,159,080.94
Settlement provisions		
Capital lent		
Trading financial assets		

Derivative financial assets		
Notes receivable	642,430,566.93	680,196,380.57
Accounts receivable	18,445,260,411.58	15,964,603,345.91
Receivable financing	469,356,116.33	1,027,226,940.21
Advances to suppliers	477,599,161.72	520,930,545.31
Insurance receivable		
Reinsurance receivables		
Contract reserve of reinsurance receivable		
Other receivables	654,794,241.77	718,089,129.10
Including: Interest receivable		
Dividend receivable		
Buying back the sale of financial assets		
Inventories	8,058,564,605.96	7,621,541,595.08
Contract assets	29,728,855.46	29,061,159.52
Assets held for sale		
Non-current asset due within one year		
Other current assets	140,830,256.92	160,607,355.66
Total current assets	33,786,109,109.85	31,848,415,532.30
Non-current assets:		
Loans and payments on behalf		
Debt investment		
Other debt investment		
Long-term account receivable		
Long-term equity investments	2,501,295,548.16	2,459,832,546.74
Other equity instruments investment	62,488,312.99	62,488,312.99
Other non-current financial assets	135,974,908.51	135,974,908.51
Investment properties	112,808,525.33	113,981,497.23
Fixed assets	850,200,561.56	868,626,258.43
Construction in progress	34,751,943.39	49,849,506.70
Productive biological asset		
Oil and gas asset		
Right-of-use assets	2,664,487,497.37	2,575,240,340.00
Intangible assets	678,354,661.52	669,926,562.82
Expense on Research and Development		
Goodwill	2,775,645,585.32	2,775,645,585.32
Long-term prepaid expenses	621,061,288.02	633,975,441.76
Deferred tax assets	154,699,087.40	129,740,169.77
Other non-current assets	466,226,309.21	459,985,769.24
Total non-current assets t	11,057,994,228.78	10,935,266,899.51
Total assets	44,844,103,338.63	42,783,682,431.81
Current liabilities:		
Short-term borrowings	3,038,581,281.11	1,930,467,146.38
Loan from central bank		
Capital borrowed		
Trading financial liability		
Derivative financial liability		

Notes payable	6,759,000,854.12	7,660,216,823.68
Accounts payable	10,610,876,048.40	9,057,718,968.14
Receipts in advance	18,591,112.89	19,289,567.44
Contract liabilities	429,473,280.23	431,303,231.37
Selling financial asset of repurchase		
Absorbing deposit and interbank deposit		
Security trading of agency		
Security sales of agency		
Employee benefits payable	225,809,878.05	340,197,125.33
Tax payable	307,116,334.60	337,164,080.19
Other payables	1,907,708,455.77	1,714,746,986.46
Including: Interest payable	37,765,231.34	31,587,062.03
Dividend payable	30,140,616.33	30,140,616.33
Commission charge and commission payable		
Reinsurance payable		
Liability held for sale		
Non-current liabilities due within one year	851,459,913.02	848,328,648.14
Other current liabilities	37,309,563.28	39,585,469.65
Total current liabilities	24,185,926,721.47	22,379,018,046.78
Non-current liabilities:		
Insurance contract reserve		
Long-term borrowings	70,137,173.89	71,637,173.89
Bonds payable		
Including: Preferred stock		
Perpetual capital securities		
Lease liabilities	1,420,668,973.13	1,375,427,877.28
Long-term payables	6,938,189.00	6,938,189.00
Long-term employee benefits payable	1,202,000.00	1,202,000.00
Provisions		
Deferred income	85,016,983.16	86,917,051.78
Deferred tax liabilities	172,433,335.41	175,948,328.93
Other non-current liabilities	584,974,923.18	664,381,065.65
Total non-current liabilities	2,341,371,577.77	2,382,451,686.53
Total liabilities	26,527,298,299.24	24,761,469,733.31
Equity		
Share capital	428,126,983.00	428,126,983.00
Other equity instrument		
Including: Preferred stock		
Perpetual capital securities		
Capital surplus	4,371,621,053.65	4,371,802,107.43
Less: Inventory shares		
Other comprehensive income	21,938,869.76	21,874,198.36
Reasonable reserve		
Surplus reserve	214,063,491.50	214,063,491.50
Provision of general risk		
Retained earnings	10,141,433,144.90	9,889,071,272.21

Total equity attributable to owners of the parent	15,177,183,542.81	14,924,938,052.50
Non-controlling interests	3,139,621,496.58	3,097,274,646.00
Total equity	18,316,805,039.39	18,022,212,698.50
Total liabilities and equity	44,844,103,338.63	42,783,682,431.81

Legal Representative: Lin Zhaoxiong

Person in charge of accounting works: Gu Guolin

Person in charge of accounting institute: Wang Ying

2. Consolidated Profit Statement

Unit: RMB/CNY

Item	Current period	Last period
I. Total operating income	17,150,856,946.54	16,049,966,325.75
Including: Operating revenue	17,150,856,946.54	16,049,966,325.75
Interest income		
Insurance gained		
Commission charge and commission income		
II. Total operating cost	16,797,706,856.47	15,663,170,079.60
Including: Operating costs	15,227,900,206.53	14,260,591,404.46
Interest expense		
Commission charge and commission expense		
Cash surrender value		
Net amount of expense of compensation		
Net amount of withdrawal of insurance contract reserve		
Bonus expense of guarantee slip		
Reinsurance expense		
Tax and surcharges	41,939,571.15	33,744,327.20
Selling expenses	1,203,497,011.57	1,080,543,941.75
Administrative expenses	264,532,679.98	237,615,927.36
R&D expense		
Finance costs	59,837,387.24	50,674,478.83
Including: Interest expenses	72,514,879.45	68,683,688.49
Interest income	16,770,723.32	18,058,735.03
Add: other incomes	25,040,832.98	13,655,624.72
Investment income (Loss is listed with “-”)	23,461,476.68	91,305,476.74
Including: Investment income from associates	41,579,383.80	92,441,826.44
Income from the derecognition of financial assets measured at amortised cost (Loss is listed with “-”)	-18,117,907.12	-4,735,905.31
Exchange income (Loss is listed with “-”)		

Net exposure hedging income (Loss is listed with “-”)		
Income from change of fair value (Loss is listed with “-”)		
Credit impairment losses/ (Loss is listed with “-”)	-25,898,207.09	-17,197,080.80
Impairment losses (Loss is listed with “-”)	-1,654,289.70	-3,488,500.85
Gain on disposal of assets (Loss is listed with “-”)	978,407.63	271,889.26
III. Operating profits (Loss is listed with “-”)	375,078,310.57	471,343,655.22
Add: Non-operating income	2,288,693.57	6,370,834.89
Less: Non-operating expenses	600,906.15	570,737.09
IV. Total profit (Loss is listed with “-”)	376,766,097.99	477,143,753.02
Less: Income tax expenses	81,994,493.36	87,580,022.00
V. Net profit (Net loss is listed with “-”)	294,771,604.63	389,563,731.02
(i) Classify by business continuity		
1. Profit or loss from continuing operations (net loss listed with “-”)	294,771,604.63	389,563,731.02
2. termination of net profit (net loss listed with “-”)		
(ii) Classify by ownership		
1. Owners of the parent	252,361,872.69	328,800,560.24
2. Non-controlling interests	42,409,731.94	60,763,170.78
VI. Other comprehensive income, net of tax	64,671.40	84,503.76
Other comprehensive income, net of tax, attributable to owners of the parent	64,671.40	84,503.76
(i) Other comprehensive income items which will not be reclassified subsequently to profit or loss		
1.Changes of the defined benefit plans that re-measured		
2.Other comprehensive income under equity method that cannot be transfer to gain/loss		
3.Change of fair value of investment in other equity instrument		
4.Fair value change of enterprise's credit risk		
5. Other		
(ii) Other comprehensive income that will be reclassified to profit or loss	64,671.40	84,503.76
1. Other comprehensive income using the equity method that may be reclassified to profit or loss	64,671.40	84,503.76
2.Change of fair value of other debt investment		
3.Amount of financial assets re-classify to other comprehensive income		
4.Credit impairment provision for other debt investment		
5.Cash flow hedging reserve		
6.Translation differences arising on		

translation of foreign currency financial statements		
7.Other		
Net after-tax of other comprehensive income attributable to minority shareholders		
VII. Total comprehensive income	294,836,276.03	389,648,234.78
Total comprehensive income attributable to owners of the parent	252,426,544.09	328,885,064.00
Total comprehensive income attributable to non-controlling interests	42,409,731.94	60,763,170.78
VIII. Earnings per share:		
(i) Basic earnings per share	0.59	0.77
(ii) Diluted earnings per share	0.59	0.77

Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, and realized 0.00 Yuan at last period for combined party.

Legal Representative: Lin Zhaoxiong

Person in charge of accounting works: Gu Guolin

Person in charge of accounting institute: Wang Ying

3. Consolidated Cash Flow Statement

Unit: RMB/CNY

Item	Current period	Last period
I. Cash flows from operating activities:		
Cash received from sales of good or rendering of services	16,757,405,030.62	15,194,724,502.12
Net increase of customer deposit and interbank deposit		
Net increase of loan from central bank		
Net increase of capital borrowed from other financial institution		
Cash received from original insurance contract fee		
Net cash received from reinsurance business		
Net increase of insured savings and investment		
Cash received from interest, commission charge and commission		
Net increase of capital borrowed		
Net increase of returned business capital		
Net cash received by agents in sale and purchase of securities		
Receipts of taxes and surcharges refunds	898,760.75	5,617,976.11
Other cash receipts relating to operating activities	145,551,765.30	209,745,502.46
Total cash inflows from operating activities	16,903,855,556.67	15,410,087,980.69
Cash payments for goods and services	15,413,374,469.33	14,094,028,880.65
Net increase of customer loans and advances		
Net increase of deposits in central bank and interbank		

Cash paid for original insurance contract compensation		
Net increase of capital lent		
Cash paid for interest, commission charge and commission		
Cash paid for bonus of guarantee slip		
Cash payments to and on behalf of employees	999,525,639.18	894,497,321.19
Payments of all types of taxes and surcharges	416,425,915.99	354,054,737.85
Other cash payments relating to operating activities	291,981,755.55	374,256,040.24
Total cash outflows from operating activities	17,121,307,780.05	15,716,836,979.93
Net cash flows from operating activities	-217,452,223.38	-306,748,999.24
II. Cash flows from investing activities:		
Cash receipts from returns of investments		2,997,441.73
Cash received from investment income		3,599,555.61
Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets	84,789.95	327,119.50
Net cash received from disposal of subsidiaries and other units		
Other cash receipts relating to investing activities		
Total cash inflows from investing activities	84,789.95	6,924,116.84
Cash payments to acquire fixed assets, intangible assets and other long-term assets	76,023,361.87	61,960,648.98
Cash payments for investments	18,322,350.00	27,079,733.00
Net increase of mortgaged loans		
Net cash payments for acquisition of subsidiaries and other business units		73,159,498.29
Cash payments related to other investing activities		
Total cash outflows from investing activities	94,345,711.87	162,199,880.27
Net cash flows from investing activities	-94,260,921.92	-155,275,763.43
III. Cash flows from financing activities		
Cash proceeds from investments by others	900,000.00	5,880,000.00
Incl: Cash receipts from capital contributions from non-controlling interests of subsidiaries	900,000.00	5,880,000.00
Cash receipts from borrowings	649,000,000.00	567,395,696.23
Other cash receipts relating to financing activities	105,391,223.35	297,416,755.19
Total cash inflows from financing activities	755,291,223.35	870,692,451.42
Cash repayments for debts	271,500,000.00	177,254,802.73
Cash payments for distribution of dividends or profit and interest expenses	63,873,455.61	59,139,307.66
Incl: Dividends or profit paid to non-controlling shareholders of subsidiaries	962,881.36	555,825.80
Other cash payments relating to financing activities	307,909,948.17	245,774,326.14
Total cash outflows from financing activities	643,283,403.78	482,168,436.53
Net cash flows from financing activities	112,007,819.57	388,524,014.89
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-450.89	-2,440.78
V. Net increase of cash and cash equivalents	-199,705,776.62	-73,503,188.56
Add: Cash and cash equivalents at beginning of the year	4,733,512,172.37	5,405,113,257.99
VI. Cash and cash equivalents at end of year	4,533,806,395.75	5,331,610,069.43

(ii) Audit report

Whether the 1st quarterly report has been audited or not

Yes No

The 1st quarterly report of the Company has not been audited.

China National Accord Medicines Corporation Ltd.

Legal representative: Lin Zhaoxiong

April 28, 2022